Bring Vaccines to Market Faster

InDevR presents a Technology Talk
in partnership with Solaris Vaccines
April 1, 10:20 ET

Innovating Vaccine Development: The Role of VaxArray in SolaVAX, a novel photochemical inactivation vaccine platform

The COVID-19 pandemic has underscored the importance of rapid vaccine development and manufacturing for emerging pathogens with significant global impacts. In addressing this challenge, we have utilized a novel photochemical method to produce whole-pathogen inactivated vaccine candidates, SolaVAX, for both COVID and influenza. The method combines UV light with riboflavin (Vitamin B2) to irreversibly damage nucleic acid while preserving key surface antigens. Our pre-clinical studies to date demonstrate improved preservation and antigenicity of viral proteins compared to traditional inactivation methods, provide significant neutralizing antibody response in animal models, as well as efficacy with the SolaVAX COVID vaccine to reduce viral replication and lung pathology in the hamster model. Integral to the development of SolaVAX has been the InDevR VaxArray® platform, a rapid, multiplexing technology that provides essential data on antigen integrity and quantification for the SolaVAX COVID and influenza vaccine development. The synergy between SolaVAX’s innovative whole-pathogen photochemical inactivation and VaxArray precise antigen quantification exemplifies a pioneering approach to vaccine development and manufacturing, offering a robust response to emerging infectious diseases.

Discover the VaxArray platform, your solution in multiplexed immunoassays designed to streamline vaccine development and analysis. This state-of-the-art system offers unparalleled precision and efficiency, empowering researchers to achieve faster, more reliable results in their efforts to advance public health.

• High-Efficiency Testing – improve at-line analysis with multiplexed immunoassays.
• Simplify Standardization – 21 CFR Part 11 compatible software and easy-to-use kits simplify standardization across workflows.
• Versatile Platform – analyze a wide range of vaccine components, from antibodies and antigens to nucleic acids.

InDevR’s VaxArray OmniFlu multiplex assay enables subtype-specific influenza vaccine quantification.

• Achieve Results Faster – fast and easy with <30 minutes of hands-on time and <1 hour to result.
• Highly Sensitive Assays – 100x more sensitive than SRID, with demonstrated equivalence for monovalent and multivalent vaccines.
• Expertly Designed Reagents – capture reagents are selected to be robust against antigenic drift.

VaxArray assays can be customized to rapidly assess mRNA construct identity, quality, and cell-based expression from a single construct or multiplexed samples.

• Custom Multiplexed Assays – multiplexed assay simplifies the development of high-valency mRNA vaccines.
• Sequence-Specific Assays – sequence-specific capture oligos are designed for assessment of mRNA identity, quantity, and integrity.
• Simplify Workflow Process – compatible with LNP formulations eliminating the need for laborious extraction procedures.